This is a working overview of 鼻内给药, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-17 and is reviewed periodically as new material appears.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。
Semax 是人工设计的七肽，序列为 Met-Glu-His-Phe-Pro-Gly-Pro，骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性，同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
After a difficult few months at Eckartsau, the Imperial Family received aid from an unexpected source. Prince Sixtus had met King George V and appealed to him to help the Habsburgs. George was reportedly moved by the request, it being only months since his imperial relatives in Russia had been executed by revolutionaries, and promised "We will immediately do what is necessary." Several British Army officers were sent to help Charles, most notably Lieutenant-Colonel Edward Lisle Strutt, who was a grandson of Lord Belper and a former student at the University of Innsbruck. On 19 March 1919, orders were received from the War Office to "get the Emperor out of Austria without delay". With some difficulty, Strutt managed to arrange a train to Switzerland, enabling the Emperor to leave the country with dignity without having to abdicate. Charles, Zita, their children and their household left Eckartsau on 24 March escorted by a detachment of British soldiers from the Honourable Artillery Company under the command of Strutt.
Hydrothermal vents, in some instances, have led to the formation of exploitable mineral resources via the deposition of seafloor massive sulfide deposits. The Mount Isa orebody, located in Queensland, Australia, is an excellent example. Many hydrothermal vents are rich in cobalt, gold, copper, and rare earth metals essential for electronic components. Hydrothermal venting on the Archean seafloor is considered to have formed Algoma-type banded iron formations, which have been a source of iron ore. Recently, mineral exploration companies, driven by the elevated price activity in the base metals sector during the mid-2000s, have turned their attention to the extraction of mineral resources from hydrothermal fields on the seafloor. Significant cost reductions are, in theory, possible. In countries such as Japan, where mineral resources are primarily derived from international imports, there is a particular push for the extraction of seafloor mineral resources. The world's first "large-scale" mining of hydrothermal vent mineral deposits was carried out by Japan Oil, Gas and Metals National Corporation (JOGMEC) in August – September, 2017. JOGMEC carried out this operation using the Research Vessel Hakurei. This mining was carried out at the 'Izena hole/cauldron' vent field within the hydrothermally active back-arc basin known as the Okinawa Trough, which contains 15 confirmed vent fields according to the InterRidge Vents Database. Two companies are currently engaged in the late stages of commencing to mine seafloor massive sulfides (SMS).
=== Infections and Disease === Type 1 diabetes is correlated with DM activation, which is hypothesized to be due to DM positively modulating the expression of disease-causing peptides in the MHC groove and thus presented to responding T cells. Experiments using the mouse model of type 1 diabetes which blocked DM or reduced its activity by overexpressing DO found a decrease in diabetes. HLA-DM is implicated in viral infections like Herpes Simplex Virus Type 1. This virus causes uneven distribution of HLA-DM in endosomes, prevents peptide catalysis, and prevents presentation of MHC class II molecules on the cell surface. HLA-DM is also implicated in celiac disease, multiple sclerosis, other autoimmune diseases, and leukemia.
== Complications == Vaginal support structures can be damaged or weakened during childbirth or pelvic surgery. Other conditions that repeatedly strain or increase pressure in the pelvic area can also compromise support. Examples are:
MDMA is an entactogen or empathogen, as well as a stimulant, euphoriant, and weak psychedelic. It is a substrate of the monoamine transporters (MATs) and acts as a monoamine releasing agent (MRA). The drug is specifically a well-balanced serotonin–norepinephrine–dopamine releasing agent (SNDRA). To a lesser extent, MDMA also acts as a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI). MDMA enters monoaminergic neurons via the MATs and then, via poorly understood mechanisms, reverses the direction of these transporters to produce efflux of the monoamine neurotransmitters rather than the usual reuptake. Induction of monoamine efflux by amphetamines in general may involve intracellular Na+ and Ca2+ elevation and PKC and CaMKIIα activation. MDMA also acts on the vesicular monoamine transporter 2 (VMAT2) on synaptic vesicles to increase the cytosolic concentrations of the monoamine neurotransmitters available for efflux. By inducing release and reuptake inhibition of serotonin, norepinephrine, and dopamine, MDMA increases levels of these neurotransmitters in the brain and periphery and thereby indirectly activates the receptors of these neurotransmitters. There are species differences in the balance of MAT activities of MDMA, with it showing greater influence on serotonin in rodents than in humans. In addition to its actions as an SNDRA, MDMA directly interacts with a number of monoamine and other receptors.
Sources: en.wikipedia.org
== The identification of PIDD1 == PIDD, now officially known as PIDD1 (p53-induced death domain protein 1), a transformation of name was necessary to avoid confusion with primary immune deficiency disorders, which are often abbreviated similarly in scientific literature. Notably, no PIDD1 orthologues have been identified in non-vertebrates, and PIDD1 paralogues have not been found in vertebrates. Initially, PIDD1 was also referred to as leucine-rich repeat and death domain containing protein (LRDD) and was independently reported by two research groups in 2000.
== History == The first benchtop detector was introduced in 2014 with detection capabilities between 120 and 240 nm. This portion of the ultraviolet spectrum had historically been restricted to bright source synchrotron facilities due to significant background absorption challenges inherent to working within the wavelength range. Further detector platform development has extended the wavelength detection range out from 120 to 430 nm.
Intentional mummification in pre-Columbian Mexico was practiced by the Aztec culture. These bodies are collectively known as Aztec mummies. Genuine Aztec mummies were "bundled" in a woven wrap and often had their faces covered by a ceremonial mask. Public knowledge of Aztec mummies increased due to traveling exhibits and museums in the 19th and 20th centuries, though these bodies were typically naturally desiccated remains and not actually the mummies associated with Aztec culture. Natural mummification has been known to occur in several places in Mexico; this includes the mummies of Guanajuato. A collection of these mummies, most of which date to the late 19th century, have been on display at El Museo de las Momias in the city of Guanajuato since 1970. The museum claims to have the smallest mummy in the world on display (a mummified fetus). It was thought that minerals in the soil had the preserving effect, however it may rather be due to the warm, arid climate. Mexican mummies are also on display in the small town of Encarnación de Díaz, Jalisco.
==== Police reform ==== Newsom has spoken in favor of Assembly Bill 1196, which would ban carotid artery restraints and choke holds in California. He said that there is no longer a place for a policing tactic "that literally is designed to stop people's blood from flowing into their brain, that has no place any longer in 21st-century practices". Newsom has signed the California Act to Save Lives and California Racial Justice Act of 2020. In September 2021, he signed legislation raising the minimum age to become a police officer from 18 to 21. Also in the bills were restrictions on the use of tear gas and a ban on police departments employing officers after misconduct or crimes. Among the bills was the George Floyd Bill, requiring officers to intervene when witnessing excessive force on the part of another officer. Newsom vetoed Assembly Bill 2681 which sought to restrict autonomous weapons citing "beneficial law enforcement use of such devices". Newsom vetoed Assembly Bill 2632, which sought to limit solitary confinement. In October 2024, Newsom vetoed Assembly Bill 2693, which sought to extend the statute of limitations for those sexually abused in juvenille facilities. In 2025, Newsom vetoed Senate Bill 274, which would have expanded the rules and regulations on law enforcement agencies, in California, use of automated license plate readers. In his veto message, he stated the proposed regulations, which would have required police to better document their searches and delete unused data within 60 days, could hinder police work.
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.